How plasma LIF predicts immune-checkpoint blockade resistance and a TLS-poor tumor microenvironment
“GPCR-ome” modulation upon PD1 / PDL1 axis blockade
Background Immunotherapy represents a novel weapon in the cancer armamentarium, with unprecedented responses observed in several indications, including metastatic melanoma and lung cancer. However, the limited response rate, accounting for approximately 30%, requires further optimization and calls for a better understanding of the mechanisms underlying sensitivity to immune checkpoint inhibitors. G protein-coupled receptors (GPCRs) are […]
Why melanoma escapes BRAF inhibitors — the AhR transcription factor behind resistance and relapse
